Results 251 to 260 of about 99,805 (324)

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source

Polypharmacy, anticholinergic burden and oral microbiome among U.S. middle-aged and older adults: a representative national survey. [PDF]

J Oral Microbiol
Wei K, Yang Y, Chen C, Yang Y, Hu K, Chen Q.   +5 more
europepmc   +1 more source

Polypharmacy as a Treatment Barrier in Autism Spectrum Disorder

Ahmed Aly
openalex   +2 more sources

Older Age Is Associated With Long‐Term Retention in Buprenorphine Treatment for Opioid Use Disorder

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Opioid use disorder (OUD) among older adults is a fast‐growing public health problem. However, little is known about treatment outcomes among older adults in office‐based buprenorphine programs. Thus, our objective was to examine how age is associated with buprenorphine treatment outcomes among adults with OUD who initiate ...
Justina L. Groeger, Tiffany Lu, Andrea Jakubowski, Chenshu Zhang, Yuting Deng, Hector Perez, Frank DiRenno, Benjamin M. Jadow, Benjamin T. Hayes, Shadi Nahvi, Chinazo O. Cunningham, Joanna L. Starrels   +11 more
wiley   +1 more source

Hyperpolypharmacy in patients with chronic kidney disease and its impact on clinical outcomes. [PDF]

Sci Rep
Mouheb A, Metzger M, Alencar de Pinho N, Jacquelinet C, Laville M, Massy ZA, Liabeuf S, Laville SM, CKD-REIN STUDY GROUP.   +8 more
europepmc   +1 more source

Investigation of Drug-Drug Interactions in Patients Older than 65 Years with Polypharmacy

Selcuk Mistik, Ayse Durmus
openalex   +1 more source

Polypharmacy, Medication-Related Burden and Antiretroviral Therapy Adherence in People Living with HIV Aged 50 and Above: A Cross-Sectional Study in Hunan, China

, 2022
Chunyuan Zheng, Jingjing Meng, Xueling Xiao, Ying Xie, Di Zhao, Honghong Wang   +5 more
openalex   +1 more source

The End of Life With Dementia in Asian Countries: Barriers, Facilitators and a Research Agenda for Advancing a Palliative Approach

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Dementia—the seventh leading cause of death globally—is most prevalent in Asia, home to over half of those affected. Yet, palliative approaches to dementia, endorsed by the World Health Organization (WHO) Global Action Plan on the Public Health Response to Dementia, and focused on improving quality of life through a holistic and ...
Chetna Malhotra, Ellie B. Andres, Chandrika Ramakrishnan   +2 more
wiley   +1 more source

Evidence-based nursing to reduce polypharmacy risks in older cholecystectomy patients. [PDF]

World J Gastrointest Surg
Deng YH, Zeng CF, Zhou J.
europepmc   +1 more source

Reducing Medication‐Related Harm Through Home‐Based Primary Care

Journal of the American Geriatrics Society, EarlyView.
This figure illustrates teaching strategies for the five domains of geriatric care, represented as the “5 M's”: Medication, Mentation, Mobility, Multi‐Complexity, and Matters Most. For each domain, Ms. T's clinical problems are listed with corresponding interventions.
Thomas J. Haferkamp, Nora Spadoni, Lauren J. Gleason   +2 more
wiley   +1 more source